Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases

References

• Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer. 1978;14(4):327–330.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Wei C, Detry M, et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol. 2011;34:603–610.
   PubMed Web of Science ®Google Scholar
• Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118:4014–4023.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Haydu LE, Kakavand H, et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer. 2014;111:292–299.
   PubMed Web of Science ®Google Scholar
• Nieder C, Marienhagen K, Geinitz H, et al. Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma? J Cancer Res Ther. 2011;7(1):47–51.
   PubMed Web of Science ®Google Scholar
• Rate WR, Solin LJ, Turrisi AT. Palliative R for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys. 1988;15(4):859–864.
   PubMed Web of Science ®Google Scholar
• Berk L, Berkey B, Rich T, et al. Randomized phase II trial of high dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys. 2007;68(3):852–857.
   PubMed Web of Science ®Google Scholar
• Knisely JP, Berkey B, Chakravarti A, et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008;71(1):79–86.
   PubMed Web of Science ®Google Scholar
• Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicenter phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003;13(1):97–103.
   PubMed Web of Science ®Google Scholar
• Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys. 1995;33(2):339–348.
   PubMed Web of Science ®Google Scholar
• Ramanujam S, Schadendorf D, Long GV. Systemic therapies for melanoma brain metastases: which drug for whom and when? Chin Clin Oncol. 2015;4(2):25.
   PubMedGoogle Scholar
• Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117:1697–1703.
   PubMed Web of Science ®Google Scholar
• Morris SL, Low SH, A’Hern RP, et al. A prognostic index that predict outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer. 2004;91:829–833.
   PubMed Web of Science ®Google Scholar
• Marcus DM, Lowe M, Khan MK, et al. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol. 2014;37:580–584.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425.
   PubMed Web of Science ®Google Scholar
• Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinic-pathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239–1246.
   PubMed Web of Science ®Google Scholar
• Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011;24:666–672.
   PubMed Web of Science ®Google Scholar
• Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118:4014–4023.
   PubMed Web of Science ®Google Scholar
• Bucheit AD, Chen G, Siroy A, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014;20:5527–5536.
   PubMed Web of Science ®Google Scholar
• Chang EL, Selek U, Hassenbusch SJ 3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004;59(4):1097–1106.
   PubMed Web of Science ®Google Scholar
• Herfarth KK, Izwekowa O, Thilmann C, et al. Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. Strahlenther Onkol. 2003;179:366–371.
   PubMed Web of Science ®Google Scholar
• Radbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer. 2004;101:825–833.
   PubMed Web of Science ®Google Scholar
• Mathieu D, Kondziolka D, Cooper PB, et al. Gamma knife radiosurgery in the management of malignant brain metastases. Neurosurgery. 2007;60(3):471–486.
   PubMed Web of Science ®Google Scholar
• Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of gamma knife surgery for melanoma brain metastases. J Neurosurg. 2011;114(3):769–779.
   PubMed Web of Science ®Google Scholar
• Bernard ME, Wegner RE, Reineman K, et al. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. J Cancer Res Ther. 2012;8(2):215–221.
   PubMed Web of Science ®Google Scholar
• Gaudy-Marqueste C, Regis JM, Muracciole X, et al. Gamma knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole brain radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:809–816.
   PubMed Web of Science ®Google Scholar
• Neal MT, Chan MD, Lucas JT Jr, et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World J Neurosurg. 2014;82(6):1250–1255.
   PubMed Web of Science ®Google Scholar
• Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117:1687–1696.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–395.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kawabe T, Sato Y, et al. Stereotactic radiosurgery for patients with multiple brain metastases: a case - matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg. 2014;121:(suppl):16-25.
   Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894.
   PubMed Web of Science ®Google Scholar
• Davey RJ, Westhuizen AV, Bowden NA, et al. Metastatic melanoma treatment: combining old and new therapies. Crit Rev Oncol Hematol. 2016;98:242–253.
   PubMed Web of Science ®Google Scholar
• Pardoll DE. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev. 2012;12:252–264.
   Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–465.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SH, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13(9):879–886.
   PubMed Web of Science ®Google Scholar
• EU Clinical Trial Register. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search
   Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, open programmed cell death. Embo J. 1992;11:3887–3895.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Ewai Y, et al. Engagement of the PD-1 immuno-inhibitor receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrozilumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
   PubMed Web of Science ®Google Scholar
• Weber JS, Minor DR, D’Angelo SP, et al. Phase III randomized, open-label study of nivolumab (anti-PD-1; BMS 936558, ONO-45-38) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA4 therapy. Ann Oncol. 2014;25:abstr LBA3.
   Web of Science ®Google Scholar
• US National Institute of Health. ClinicalTrials.gov.2015. Available from: https://www.clinicaltrials.gov/Identifier:NCT02320058
   Google Scholar
• Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol. 2013;31:abstr90–10.
   Web of Science ®Google Scholar
• Gerber NK, Young RJ, Barker CA, et al. Ipilimumab and whole brain radiotherapy for melanoma brain metastases. J Neuroncol. 2015;121:159–165.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Menzies AM, et al. A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: the Anti-PD1 Brain Collaboration (ABC study). J Clin Oncol. 2016;34(suppl):abstr TPS9591.
   Google Scholar
• Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys. 2014;88:986–997.
   PubMed Web of Science ®Google Scholar
• Muller-Brenne T, Rudolph B, Schmidberger H. Successful therapy of a cerebral metastasized malignant melanoma by whole-brain radiation therapy and ipilimumab. J Dtsch Dermatol Ges. 2003;9:787–788.
   Google Scholar
• Bot I, Blank CU, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol. 2012;259:1976–1978.
   PubMed Web of Science ®Google Scholar
• Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015;3:50.
   PubMed Web of Science ®Google Scholar
• Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2:899–906.
   PubMed Web of Science ®Google Scholar
• Knisely JP, Yu JB, Flanigan J, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117:227–233.
   PubMed Web of Science ®Google Scholar
• Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23:191–195.
   PubMed Web of Science ®Google Scholar
• Tazi K, Hataway A, Chiuzan C, et al. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med. 2015;4:1–6.
   PubMed Web of Science ®Google Scholar
• Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92:368–375.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 2016;27:434–441.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Abuodeh YA, Echevarria MI, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016;27(12):2288–2294.
   PubMed Web of Science ®Google Scholar
• Qin R, Olson A, Singh B, et al. Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab. Int J Radiat Oncol Biol Phys. 2016;96(1):72.
   PubMed Web of Science ®Google Scholar
• Patel KR, Shoukat S, Oliver DE, et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol. 2015 May 16;1.
   Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–332.
   PubMed Web of Science ®Google Scholar
• Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:1087–1095.
   PubMed Web of Science ®Google Scholar
• Melnik I, Lotem M, Yoffe B. A new role of vemurafenib as a neoadjuvant treatment of auxiliary and brain melanoma metastases. Case Rep Oncol Med. 2013; Article ID 794239, 3 pages.
   Google Scholar
• Dummer R, Goldinger SM, Turadiotherapyschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014;50:611–621.
   PubMed Web of Science ®Google Scholar
• Kefford RF, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Pigment Cell Melanoma Res. 2013;26:965.
   Google Scholar
• Dzienis MR, Atkinson VG. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res. 2014;24:349–353.
   PubMed Web of Science ®Google Scholar
• Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522–2529.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Lum T, Wilmott JS, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol. 2014;38:377–382.
   PubMed Web of Science ®Google Scholar
• Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial. Lancet. 2012;379:1893–1901.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–1703.
   PubMed Web of Science ®Google Scholar
• Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014;20:1965–1977.
   PubMed Web of Science ®Google Scholar
• van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94–109.
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80–93.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovsky DL, Gogas H, et al. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/Kmutation-positive cutaneous melanoma. J Clin Oncol. 2015;32:abstr 9011.
   Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–1876.
   PubMed Web of Science ®Google Scholar
• Narayana A, Mathew M, Tam M, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neuroncol. 2013;113:411–416.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Freilich J, Sloot S, et al. Linac-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neuroncol. 2015;122:121–126.
   PubMed Web of Science ®Google Scholar
• Gaudy-Marqueste C, Carron R, Delsanti C, et al. On demand gamma-knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol. 2014;25(10):2086–2091.
   PubMed Web of Science ®Google Scholar
• Kotecha R, Venur VA, Murphy ES, et al. Impact of BRAF mutation on outcome following stereotactic radiosurgery in melanoma brain metastases. Int J Radiat Oncol Biol Phys. 2015;93:3.
   Google Scholar
• Gallaher IS, Watanabe Y, De For TE, et al. BRAF mutation is associated with improved local control of melanoma brain metastases treated with gamma knife radiosurgery. Front Oncol. 2016;6:1–8.
   PubMed Web of Science ®Google Scholar
• Ly D, Bagshaw HP, Anker CJ, et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg. 2015;123:395–401.
   PubMed Web of Science ®Google Scholar
• Bindiya GP, Ahmed KA, Johnstoneb P, et al. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Research. 2016;26(4):382–386.
   PubMed Web of Science ®Google Scholar
• Wolf A, Zia S, Verma R, et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neuroncol. 2016;127:607–615.
   PubMed Web of Science ®Google Scholar
• Xu Z, Lee CC, Ramesh A, et al. BRAF V600E mutation and BRAF kinase inhibitor in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg. 2016;20:1–9.
   Google Scholar
• Patel KR, Chowdhay M, Switchenko JM, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res. 2016;26(4):387–394.
   PubMed Web of Science ®Google Scholar
• Lin N, Lee E, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncology. 2015;16:e270–78.
   PubMed Web of Science ®Google Scholar